Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Galderma Announces ASPIRE Rewards Program Reaches One Million Members

Galderma
Posted on: 25 Oct 18
Galderma Announces ASPIRE Rewards Program Reaches One Million Members

PR Newswire

FORT WORTH, Texas, Oct. 25, 2018

FORT WORTH, Texas, Oct. 25, 2018 /PRNewswire/ -- Galderma Laboratories, L.P., a global leader focused on meeting the world's increasing skin health needs, announced today that their ASPIRE Galderma Rewards program has reached the one million member milestone. ASPIRE Galderma Rewards is a loyalty program for consumers and aesthetic providers who use Galderma aesthetic injectable treatments, such as Dysport® (abobotulinumtoxinA) for Injection, the Restylane® family of fillers and Sculptra®Aesthetic. To celebrate 1 million loyalists in less than 3.5 years, Galderma will announce the winner of a consumer sweepstakes for ASPIRE members this month.

"As a company invested in growing the aesthetics market, we are thrilled to have a patient loyalty program with such an extensive reach in a short time," said Alisa Lask, General Manager & Vice President of the U.S. Aesthetic Business at Galderma. "Galderma plans to continue investing in the program by adding tools and resources to bring enhanced promotions, sharable social media content, and the ability for healthcare providers to leverage powerful big data analytics to drive growth in their practice."

The ASPIRE Galderma Rewards program is designed to help aesthetic providers maintain and grow a loyal patient base, by allowing them to enrich the patient experience with rewards and incentives. Ninety-eight percent (98%) of ASPIRE Galderma Rewards patients have returned to the same aesthetic provider for repeat treatments.1 The program is unique in the aesthetics industry in that it is currently the only program to offer aesthetic providers with practice intelligence data to help them maximize practice growth. Enrollment in the ASPIRE Galderma Rewards program has continued to accelerate each year, and Galderma looks forward to continued growth.

"Galderma has been an innovative leader in helping me expand the services and solutions I can offer to my patients," said Dr. Justin Harper*, Founder of Juvly Aesthetics with 11 locations in New York City, Ohio, Florida, Minnesota and Wisconsin and a top five user of the ASPIRE platform. "Having access to this strong client loyalty program allows my entire team to engage more with our clients, build loyalty, and provide industry-leading savings on their treatments."

*Paid Galderma Consultant

About Galderma
Galderma, Nestlé Skin Health's medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galdermausa.com.

For more information, please visit www.galdermausa.com and www.galderma.com.

To earn exclusive rewards, bonuses and discounts on Galderma's aesthetic treatments, join the ASPIRE Rewards program. To learn more about ASPIRE, visit www.aspirerewards.com.

Dysport® (AbobotulinumtoxinA) for Injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients less than 65 years of age.

Important Safety Information Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including upper limb spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

CONTRAINDICATIONS

  • Hypersensitivity to any botulinum toxin product or excipients
  • Allergy to cow's milk protein
  • Infection at the proposed injection site(s)

WARNINGS AND PRECAUTIONS

  • The potency Units of Dysport are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of Dysport cannot be compared to or converted into units of any other botulinum toxin products.
  • Recommended dose and frequency of administration should not be exceeded.
  • Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties.
  • Concomitant neuromuscular disorder may exacerbate clinical effects of treatment.
  • Dysport contains human albumin. There is a risk for transmission of Creutzfeldt-Jakob disease (CJD) however, no cases of transmission of viral diseases or CJD have ever been identified for albumin.

ADVERSE REACTIONS

  • In clinical studies, the most frequently reported adverse events (≥2%) were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, nausea, and blood present in urine.

DRUG INTERACTIONS

  • Concomitant use of Dysport and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of the botulinum toxin may be potentiated.
  • Anticholinergic drugs may potentiate systemic anticholinergic effects.
  • Excessive weakness may be exacerbated by administration of different botulinum neurotoxins and/or muscle relaxants during the course of treatment with Dysport.

USE IN SPECIFIC POPULATIONS

  • Dysport is not recommended for use in children or pregnant women.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Dysport Full Prescribing Information including Medication Guide at DysportUSA.com.

Important Safety Information
The Restylane family of products includes Restylane®, Restylane-L®, Restylane® Lyft with Lidocaine, Restylane® Silk, Restylane® Refyne, and Restylane® Defyne.

APPROVED USES
Restylane®and Restylane-are for mid-to-deep injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Restylane®and Restylane-L®are also indicated for injection into the lips in patients over the age of 21.

Restylane® Lyft with Lidocaine is for deep implantation into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and for cheek augmentation and for the correction of age-related midface contour deficiencies in patients over the age of 21. Restylane®Lyft with Lidocaine is also indicated for injection into the subcutaneous plane in the dorsal hand to correct volume deficit in patients over the age of 21.

Restylane® Silk is for lip augmentation and for correction of perioral wrinkles in patients over the age of 21.

Restylane® Refyne is for mid-to-deep injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in patients over the age of 21.

Restylane® Defyne is for mid-to-deep injection into the facial tissue for the correction of moderate to severe deep facial wrinkles and folds, such as nasolabial folds, in patients over the age of 21.

Are there any reasons why I should not use products within the Restylane®family? (Contraindications)

To ensure a safe procedure, your doctor will talk to you about your medical history to determine if you are an appropriate candidate for treatment. You should not use products within the Restylane family if:

  • You have severe allergies with a history of severe reactions (anaphylaxis)
  • You are allergic to lidocaine or to any of the gram-positive bacterial proteins used to make hyaluronic acid
  • You are prone to bleeding or have been diagnosed with a bleeding disorder

Are there other precautions that I should discuss with my doctor?

  • Tell your doctor if you are breastfeeding, pregnant, or trying to become pregnant. The safety of these products for use during pregnancy, or in women who are breastfeeding, has not been studied
  • Restylane, Restylane-L, Restylane® Lyft with Lidocaine, Restylane Refyne and Restylane Defyne are intended to treat facial wrinkles and folds, such as nasolabial folds. Restylane and Restylane-L are also intended for lip enhancement. Restylane® Lyft with Lidocaine is also intended for injection in the dorsal hand to correct volume loss. Treatments in other areas of the face or body have not been evaluated in clinical studies.
  • The safety and effectiveness of Restylane® Silk for areas other than the lips and perioral area have not been evaluated in clinical studies.
  • Tell your doctor if you have any history of scarring, particularly thick and stiff scars, or any pigmentation (skin color) disorders. These side effects can occur with hyaluronic acid fillers in general.
  • Tell your doctor if you are planning other laser treatments or a chemical peel, as there is a possible risk of inflammation at the treatment site if these procedures are performed after treatment
  • Patients who experience skin injury near the site of injection with these products may be at a higher risk for side effects
  • Tell your doctor if you are on any medications to decrease your body's immune response (immunosuppressive therapy). Using these medications may increase your risk of bruising or bleeding at the gel injection site.
  • Tell your doctor if you are using any "blood thinners" such as aspirin, warfarin, or any other medications that affect bleeding. Using these medications may increase your risk of bruising or bleeding at the gel injection site.
  • The use of these products on gel injection sites with skin sores, pimples, rashes, hives, cysts, or infections should be postponed until healing is complete. Use of product in these areas could delay healing or make your skin problems worse.
  • Tell your doctor if you have diseases, injuries, or disabilities of the hand.

What are the possible side effects?
The most commonly observed side effects are swelling, redness, pain, bruising, headache, tenderness, lump formation, itching at the injection site, and impaired hand function. These are typically mild in severity and typically resolve in less than 7 days in nasolabial folds and less than 14 days in lips. Serious but rare side effects include delayed onset infections, recurrence of herpetic eruptions, and superficial necrosis at the injection site.

One of the risks with using this product is unintentional injection into a blood vessel. The chances of this happening are very small, but if it does happen, the complications can be serious, and may be permanent. These complications, which have been reported for facial injections, can include vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin.

As with all skin injection procedures, there is a risk of infection.

To report a side effect with any of the Restylane products, please call Galderma Laboratories, L.P at 1-855-425-8722.

The Restylane family of products is available only through a licensed practitioner. Complete Instructions for Use are available at www.RestylaneUSA.com.

Important Safety Information
Indication : Sculptra® Aesthetic (injectable poly-L-lactic acid) is indicated for use in people with healthy immune systems as a single regimen for the correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles in which deep dermal grid pattern (cross-hatch) injection technique is appropriate.

Sculptra® Aesthetic should not be used by people that are allergic to any ingredient of the product or have a history of keloid formation or hypertrophic scarring. Safety has not been established in patients who are pregnant, lactating, breastfeeding, or under 18 years of age.

Sculptra® Aesthetic has unique injection requirements and should only be used by a trained physician. Contour deficiencies should not be overcorrected because they are expected to gradually improve after treatment.

Sculptra® Aesthetic should not be injected into the blood vessels as it may cause vascular occlusion, infarction or embolic phenomena. Use at the site of skin sores, cysts, pimples, rashes, hives or infection should be postponed until healing is complete. Sculptra® Aesthetic should not be injected into the red area (vermillion) of the lip or in the peri-orbital area.

The most common side effects after initial treatment include injection site swelling, tenderness, redness, pain, bruising, bleeding, itching and lumps. Other side effects may include small lumps under the skin that are sometimes noticeable when pressing on the treated area. Larger lumps, some with delayed onset   with or without inflammation or skin discoloration, have also been reported.

Sculptra® Aesthetic is available only through a licensed practitioner. View the complete instructions for use at www.SculptraAesthetic.com

© 2018 Galderma Laboratories, L.P. The Dysport trademark is used under license. All trademarks are the property of their respective owners.

1Data on file. ASPIRE database. Fort Worth, TX: Galderma Laboratories, L.P., Accessed on February 27, 2018.

View original content to download multimedia:http://www.prnewswire.com/news-releases/galderma-announces-aspire-rewards-program-reaches-one-million-members-300737582.html

SOURCE Galderma

PR Newswire
www.prnewswire.com

Last updated on: 25/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.